Search 237 product updates by drug, renal measure or dialysis term. Each result identifies the formulation, the label used and the limits of its renal guidance.
For adult nonvalvular AF, do not use edoxaban above CrCl 95 mL/min. Give 60 mg once daily at CrCl above 50 through 95, or 30 mg once daily at 15-50 mL/min. Use below 15 is not recommended.
Limits and monitoring
The upper clearance restriction applies to AF. DVT/PE has separate eligibility, initial parenteral therapy, weight and interacting-drug criteria.
At eGFR 45 or higher, renal impairment alone requires no dosage change. Use is not recommended from 30 to below 45. Below 30, in ESRD, or during dialysis the combination is contraindicated.
Limits and monitoring
All eGFR thresholds are in mL/min/1.73 m2. Verify both components of the prescribed tablet.
At eGFR 45 or higher, renal impairment alone requires no dosage change. Use is not recommended from 30 to below 45. Below 30, in ESRD, or during dialysis the combination is contraindicated.
Limits and monitoring
All eGFR thresholds are in mL/min/1.73 m2. Verify both components of the prescribed tablet.
The usual combination regimen can be used at CrCl above 30 mL/min. The renal section favors a loop diuretic in more severe impairment and discourages the fixed thiazide combination there.
Limits and monitoring
Evaluate volume status and renal function. Do not use single-ingredient irbesartan clearance data to dismiss the diuretic limitation.
At CrCl below 30 mL/min or in ESRD, potent CYP3A inhibitors or inducers contraindicate maraviroc. In adults without such interacting drugs, postural hypotension on 300 mg twice daily warrants reduction to 150 mg twice daily.
Limits and monitoring
Consider use in this renal population only if alternatives are unavailable. Check concomitant drugs, age and orthostatic symptoms.
